ABBV AbbVie Inc. Loading...

From CVS earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
13:00
Feb 10 ◎
David Joyner CEO, CVS Health Corporation CVS Q4 FY25 call
CVS sees biosimilar adoption, particularly of Humira biosimilars, as a key cost-saving lever, with 96% adoption and $1.5B in savings, creating pressure on brand-name drug manufacturers. — CVS's aggressive biosimilar strategy is a major force driving down pharmaceutical prices and challenging brand-name drug pricing power.
ABBV
MED

About ABBV Analyst Coverage

Buzzberg tracks ABBV (AbbVie Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: David Joyner.